Alzheon is an American clinical-stage

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

company based in

Framingham, Massachusetts Framingham () is a city in the Commonwealth of Massachusetts in the United States. Incorporated in 1700, it is located in Middlesex County and the MetroWest subregion of the Greater Boston metropolitan area. The city proper covers with a popu ...

. The company is developing

medicines A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and rel ...

for patients with

Alzheimer's disease Alzheimer's disease (AD) is a neurodegeneration, neurodegenerative disease that usually starts slowly and progressively worsens. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in short-term me ...

and other

neurological Neurology (from el, νεῦρον (neûron), "string, nerve" and the suffix -logia, "study of") is the branch of medicine dealing with the diagnosis and treatment of all categories of conditions and disease involving the brain, the spinal ...

and

psychiatric disorders A mental disorder, also referred to as a mental illness or psychiatric disorder, is a behavioral or mental pattern that causes significant distress or impairment of personal functioning. Such features may be persistent, relapsing and remitti ...

History

Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, a veteran of Alzheimer's drug programs, who serves as president and CEO of the organization. Alzheon completed a $10 million Series A round of financing in April 2015 and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016. In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairman of Board of Directors. In August 2020, Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging, part of the National Institutes of Health. The grant is to support the Phase 3 clinical trial of ALZ-801 that began in May 2021

Pipeline

Alzheon's leading candidate, ALZ-801, is an oral prodrug of the active agent tramiprosate that targets neurotoxic soluble amyloid oligomers, and received Fast Track designation from the FDA in 2017. ALZ-801 oral tablet is being evaluated in Phase 2 biomarker study in early Alzheimer's disease patients with homozygous and heterozygous APOE4 genotype. ALZ-801 is also in Phase 3 clinical development for high-risk homozygous APOE4/4 patients with early Alzheimer's Disease. Patients with two alleles of APOE4 have up to 20 times the risk of developing Alzheimer's disease. Alzheon completed a $50 million Series D in April 2022 and will use the funds to complete ALZ-801 clinical trials.

References

{{Reflist, 30em Biopharmaceutical companies Pharmaceutical companies of the United States Companies based in Framingham, Massachusetts Pharmaceutical companies established in 2013 Health care companies based in Massachusetts